ClinicalTrials.gg
Not yet recruitingNCT07745764INJECTHEALUpdated Aug 4, 2026

INJECTHEAL - Investigation of Chronic Wound Exudate and Biofilm

An observational study in Chronic Ulcers: Non-healing Deep Cavity Wounds (e.g., Diabetic Foot Ulcers, Arterial Ulcers, Post-surgical Wound Healing Disorders), sponsored by Barbara Wolff-Winiski. Not yet recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-04.

Sponsored by Barbara Wolff-Winiski · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
72
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 37 studies in Diabetic Foot with a site in Germany — 4 open to participants now, 4 under way, none of them phase 3. Diabetic Foot · Germany.

Started
2026
with 1 other
Observational
8 of 37
1 open now
Registered
36th of 37
by date
Lead sponsor
1 of 37
Barbara Wolff-Winiski

Among the 37 studies in Diabetic Foot with a site in Germany, this one is one of 2 that started in 2026, is one of 8 observational ones, and was the 36th registered.

Diabetic Foot

1,079 studies on the registry are indexed under Diabetic Foot; 221 are open to participants now.

Browse Diabetic Foot studies →

Open to participants now

4 of the 37 studies in Diabetic Foot with a site in Germany are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 139 Diabetic Foot studies recruiting now, 98 (71%) set no upper age limit and 12 (9%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies in Diabetic Foot with a site in Germany, or all of them as a file.
02

Study summary

This prospective observational study will collect routine clinical waste material from 72 adults with chronic, non-healing wounds, including wound exudate from negative pressure therapy containers or sponges and wound biofilm/debridement material. Samples and routine clinical wound data will be used to test INJECTHEAL hydrogel components and other wound healing therapeutics, and identify molecular, biochemical, and microbiological biomarkers linked to wound healing.

Read the detailed description

The Horizon Europe project INJECTHEAL platform is designed to provide a biomimetic matrix for tissue regeneration and to enable controlled delivery of antibacterial, anti-inflammatory, and pro-angiogenic components.

This is a monocentric, prospective, exploratory, non-interventional observational study. It involves the collection of biological material and health-related personal data from adults with chronic, non-healing deep cavity wounds who are treated as part of routine clinical care. Study data will be documented in doubly pseudonymized form.

Biological material will consist of routine clinical waste material. Wound exudate will be obtained from negative pressure wound therapy and biofilm/debridement material will be collected from medically indicated sharp or surgical debridement. Where feasible, longitudinal sampling will be performed during routine wound care visits, with approximately 3 to 5 visits expected per participant.

Components of the INJECTHEAL hydrogel system and other wound healing therapeutics will be evaluated for their capacity to mitigate or reverse inhibitory effects of chronic wound material on regenerative cellular functions.

Further analyses will include biochemical and molecular characterization of wound exudates, including total protein, proteases and protease activity, growth factors, cytokines, proteomic profiles, and metabolomic profiles. Biofilm samples will be analyzed using microbiological and molecular methods, including bacterial rRNA16S metagenomic sequencing and patient-specific 3D biofilm models to assess antibacterial effects of INJECTHEAL components.

03

Conditions studied

  • Chronic Ulcers: Non-healing Deep Cavity Wounds (e.g., Diabetic Foot Ulcers, Arterial Ulcers, Post-surgical Wound Healing Disorders)

Browse trials for

Keywords

  • Chronic Wound
  • Non-healing Wound
  • Wound healing
  • Wound Exudate
  • Wound Biofilm
  • Wound Microbiome
  • Fibroblast proliferation
  • Negative pressure wound therapy
  • rRNA 16S
  • Deep cavity wounds
  • Hydrogel
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults with chronic, non-healing deep cavity wounds, such as diabetic foot ulcers, arterial ulcers of the lower extremity, post-surgical non-healing wounds, or wounds with delayed healing, who are treated as part of routine clinical care and who undergo routine negative pressure wound therapy and/or medically indicated sharp or surgical debridement.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • Type I or type II diabetes with lower extremity deep cavity ulcers
  • Arterial leg ulcers with lower extremity deep cavity ulcers
  • Surgical deep cavity non-healing wounds
  • Wounds with delayed healing
  • Routine treatment with negative pressure wound therapy
  • Routine sharp or surgical debridement
  • Sufficient wound exudate available (min. of 2 ml per visit)
  • Patient is informed about the study and has given

Exclusion criteria

Exclusion Criteria:

  • Age ≤ 18 years
  • Multiple substance abuse (poly-toxicomania)
  • No signed declaration of consent or incapable of giving an informed written consent
  • Proven active infections with , or HPV
  • Active pregnancy
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
72 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Patients with chronic wounds

    Other: standard of care

Interventions

  • Otherstandard of care

    Patients enrolled in this observational study receive standard of care. Treatment, ointments, compression and bandages will be registered at every visit.

06

What researchers measure

Primary outcomes

  1. Wound Exudate and Biofilm Extract Effects on Proliferation of Primary Human Fibroblasts

    Proliferation (Optical density)

    Time frame: Four weeks

  2. Antibacterial Effects of INJECTHEAL Components on Patient-Specific 3D Wound Biofilm Samples

    Bacterial growth (Colony forming units)

    Time frame: Four weeks

Secondary outcomes

  1. Effects of Wound Material and Test Substances on Cell Migration

    Cellular migration (Percent surface area covered)

    Time frame: Four weeks

  2. Effects of Wound Exudate and/or Biofilm Extracts on Proliferation of Additional Wound-Relevant Cell Types

    Proliferation (Optical density)

    Time frame: Four weeks

  3. Pro-Inflammatory Cytokine Secretion in Wound-Relevant Cell Types

    Measurement of pro-inflammatory cytokines (ng/ml)

    Time frame: Four weeks

  4. Protein content of wound exudate

    Quantification of total protein (mg/ml)

    Time frame: Four weeks

  5. Proteomics profile of wound exudate

    Proteomics analysis of wound exudate (-log10(p-value))

    Time frame: Four months

  6. Bacterial composition of wound biofilm by rRNA16S sequencing

    Bioburden, Diversity and Pathogens

    Time frame: Four weeks

  7. Correlation of ex vivo/in vitro, biochemical, proteomic, metabolomic, and microbiological findings with routinely collected clinical data

    Correlation of laboratory findings with clinical wound trajectory

    Time frame: Four weeks

  8. Effects of Wound Material and Test Substances on Extracellular Matrix Formation

    Extracellular Matrix Formation (Optical density)

    Time frame: 4 weeks

  9. Inflammatory Marker Response in Wound-Relevant Cell Types

    Inflammatory markers (Mean fluorescence intensity)

    Time frame: 4 weeks

  10. Metabolomics profile of wound exudate

    Metabolomics analysis of wound exudate (Ion counts)

    Time frame: 4 months

  11. Protease acitivty

    Proteases (nM)

    Time frame: 4 weeks

07

Study locations

1 site
08

References and documents

Publications

  • Alavi A, Sibbald RG, Phillips TJ, Miller OF, Margolis DJ, Marston W, Woo K, Romanelli M, Kirsner RS. What's new: Management of venous leg ulcers: Approach to venous leg ulcers. J Am Acad Dermatol. 2016 Apr;74(4):627-40; quiz 641-2. doi: 10.1016/j.jaad.2014.10.048. PubMed 26979354 ↗
  • Doerfler P, Schoefmann N, Cabral G, Bauer W, Berli MC, Binder B, Borst C, Botter S, French LE, Goerge T, Hafner J, Hartmann D, Hogh A, Hoetzenecker W, Holzer-Geissler JCJ, Kamolz LP, Kofler K, Luger T, Nischwitz SP, Popovits M, Rappersberger K, Restivo G, Schlager JG, Schmuth M, Stingl G, Stockinger T, Stroelin A, Stuetz A, Umlauft J, Weninger WP, Wolff-Winiski B. Development of a Cellular Assay as a Personalized Model for Testing Chronic Wound Therapeutics. J Invest Dermatol. 2025 Mar;145(3):631-644.e22. doi: 10.1016/j.jid.2024.05.029. Epub 2024 Jul 1. PubMed 38960086 ↗
  • Falanga V, Isseroff RR, Soulika AM, Romanelli M, Margolis D, Kapp S, Granick M, Harding K. Chronic wounds. Nat Rev Dis Primers. 2022 Jul 21;8(1):50. doi: 10.1038/s41572-022-00377-3. PubMed 35864102 ↗
  • Sen CK, Gordillo GM, Roy S, Kirsner R, Lambert L, Hunt TK, Gottrup F, Gurtner GC, Longaker MT. Human skin wounds: a major and snowballing threat to public health and the economy. Wound Repair Regen. 2009 Nov-Dec;17(6):763-71. doi: 10.1111/j.1524-475X.2009.00543.x. PubMed 19903300 ↗
  • Versey Z, da Cruz Nizer WS, Russell E, Zigic S, DeZeeuw KG, Marek JE, Overhage J, Cassol E. Biofilm-Innate Immune Interface: Contribution to Chronic Wound Formation. Front Immunol. 2021 Apr 9;12:648554. doi: 10.3389/fimmu.2021.648554. eCollection 2021. PubMed 33897696 ↗

Individual participant data

Plan to share: Yes — Individual patient data can be shared anonymized upon contact with PI, after publication of primary results.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Data will be avaiable after publication of primary results.

Access criteria: Access upon request via email to Principal Investigator.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2026; primary completion for Apr 2028, 20 months later.

Of 90 observational studies under Diabetic Foot, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 59. This study's planned 20 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 23, 2026
First posted
Aug 4, 2026
StartEst.
Aug 1, 2026
Primary completionEst.
Apr 10, 2028
CompletionEst.
Apr 10, 2028
Last update
Aug 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07745764
Lead sponsor
Barbara Wolff-Winiski
Responsible party
Barbara Wolff-Winiski (Chief Scientific Officer, Akribes Biomedical GmbH) — Sponsor-investigator
First posted
Aug 4, 2026
Start date
Aug 1, 2026 (estimated)
Primary completion
Apr 10, 2028 (estimated)
Completion
Apr 10, 2028 (estimated)
Last update
Aug 4, 2026

Study contacts

Dr. med. Julian-Dario Rembe, Ph.D.
Contact
julian-dario.rembe@med.uni-duesseldorf.de
+49 211 81 - 07163‬‬‬‬‬‬‬‬‬‬‬‬
Dr. Barbara Wolff-Winiski, MBA
Contact
barbara.wolff-winiski@akribes-biomedical.at
+43 1 226 2022 02
Dr. Barbara Wolff-Winiski, MBA
study director · Akribes/Biomedical GmbH, Dr. Bohr-Gasse 7 A-1030 Vienna, Austria
Dr. med. Julian-Dario Rembe, Ph.D.
principal investigator · Heinrich-Heine University, Duesseldorf; Moorenstr. 5 40225 Düsseldorf

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion